Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CER-001 infusions in adults with homozygous familial ApoA-I deficiency
NL-OMON39134Phase 2Active, not recruiting
- Sponsor
- ABIONYX Pharma
- Start
- Feb 2012
- Modality
- Recombinant Proteins and Enzymes, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of CER-001 in Familial high-density lipoprotein deficiency (FHD) and primary hypoalphalipoproteinemia 2, sponsored by ABIONYX Pharma. Primary endpoints: Single dose pharmacokinetics of ApoA-I following the first and final doses, Peak free cholesterol levels and 1 more. Started Feb 2012; status: active, not recruiting.
02
Drugs
CER-001
03
Conditions
Familial high-density lipoprotein deficiency (FHD)primary hypoalphalipoproteinemia 2
Beyond the preview
Go deeper on NL-OMON39134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39134.